Keros licenses elritercept to Takeda for $200M upfront; milestones up to $1.1B

Keros Therapeutics, Inc.

Upfront payment of $200M; eligible for up to $370M in development/commercial milestones and $740M in sales milestones.
Tiered royalties on net sales in Territory (ex-China) from low double-digits to high teens, subject to reductions.
Elritercept in Phase 2 for MDS and myelofibrosis; Phase 3 RENEW trial for MDS to begin enrollment soon.
Keros expects upfront proceeds to extend cash runway into Q4 2028, supporting cibotercept and KER-065 programs.
Agreement effective subject to HSR Act clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.